Evaluation of the clinical efficacy of asenapine in schizophrenia.

Expert Opinion on Pharmacotherapy
Arpi Minassian, Jared W Young

Abstract

Asenapine is a new atypical antipsychotic medication with high affinity for D(2) and 5HT(2A) receptors that has been approved by the FDA in adults for the acute treatment of schizophrenia in the USA. The purpose of this review is to describe the compound and examine whether it addresses some of the unmet clinical needs in treating schizophrenia. The development of asenapine is described with attention to its chemistry, pharmacodynamic and pharmacokinetic profile. Preclinical and clinical trials of safety and efficacy are reviewed. The advantages and disadvantages of asenapine relative to other antipsychotic medications are discussed. Asenapine will be evaluated for whether it: i) causes a reduction in symptoms of schizophrenia; ii) has a side-effect profile minimizing extrapyramidal symptoms, weight gain and cardiac effects; and iii) affects negative and/or cognitive symptoms. Asenapine is a recently approved agent with an acceptable cardiometabolic profile and exhibits similar efficacy as other antipsychotic medications, primarily on positive symptoms of schizophrenia. Relatively less weight gain compared with other agents may confer a notable advantage. Sublingual administration may have positive and negative effects on patie...Continue Reading

References

Mar 1, 1990·Pharmacology, Biochemistry, and Behavior·B CostallD M Tomkins
Apr 15, 1993·European Journal of Pharmacology·M KuoppamäkiJ Hietala
Mar 1, 1996·The American Journal of Psychiatry·M F Green
Jul 28, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·T I PriorG B Baker
Dec 26, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·H O KalkmanD Hoyer
Jun 4, 2002·The American Journal of Psychiatry·David M Taylor
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mark A Geyer, Bart Ellenbroek
Mar 16, 2004·CNS Drugs·Jeffrey A Lieberman
Aug 6, 2005·Methods and Findings in Experimental and Clinical Pharmacology·J S Silvestre, J Prous
Jan 12, 2007·Basic & Clinical Pharmacology & Toxicology·Edoardo Spina, Jose de Leon
Jul 17, 2007·European Archives of Psychiatry and Clinical Neuroscience·Michael RiedelHans-Jürgen Möller
Oct 27, 2007·The Journal of Clinical Psychiatry·Steven G PotkinJohn Panagides
Jan 4, 2008·The American Journal of Psychiatry·Keith H NuechterleinStephen R Marder
Mar 1, 2008·Journal of Psychopharmacology·V A CurtisE Sacchetti
Mar 1, 2008·Journal of Psychopharmacology·M ShahidE H F Wong
May 3, 2008·Psychiatric Services : a Journal of the American Psychiatric Association·William T Carpenter, Robert W Buchanan
Oct 4, 2008·Psychiatric Services : a Journal of the American Psychiatric Association·Paul N PfeifferMarcia Valenstein
Oct 18, 2008·Psychopharmacology·David S TaitVerity J Brown
Dec 17, 2008·Schizophrenia Bulletin·Keith H NuechterleinMartin Sarter
Feb 18, 2009·The Australian and New Zealand Journal of Psychiatry·Simon ChapmanKevin McGeechan
May 23, 2009·Psychopharmacology·Hugh M MarstonMohammed Shahid
Aug 20, 2009·CNS Drugs·Juliane Weber, Paul L McCormack
Oct 17, 2009·Bipolar Disorders·Roger S McIntyreJohn Panagides
Oct 20, 2009·The International Journal of Neuropsychopharmacology·Yong Kee ChoiFrank I Tarazi
Oct 22, 2009·Journal of Clinical Pharmacology·Sunny ChapelRichard L Lalonde
Apr 15, 2010·The Annals of Pharmacotherapy·Jehan Marino, Joshua Caballero

❮ Previous
Next ❯

Citations

Apr 3, 2013·European Journal of Clinical Pharmacology·Melvin GeorgeSteven Aibor Dkhar
Jun 10, 2011·Neuropsychiatric Disease and Treatment·Maurizio PompiliPaolo Girardi
Jul 5, 2011·Expert Review of Neurotherapeutics·Maurizio PompiliPaolo Girardi
Aug 2, 2014·Expert Opinion on Drug Safety·Bernardo Dell'OssoAlfredo Carlo Altamura
Feb 20, 2016·CNS Drugs·Paul D Shilling, David Feifel
Jan 25, 2012·Drug Discovery Today·Jens-Uwe PetersManfred Kansy
Mar 23, 2011·Current Opinion in Pharmacology·H Y Meltzer, B W Massey
Mar 18, 2011·British Journal of Pharmacology·Jared W YoungMark A Geyer
May 6, 2014·Expert Opinion on Drug Safety·Leslie Citrome
May 8, 2016·Journal of Child and Adolescent Psychopharmacology·Dhrubajyoti BhuyanSamir Kumar Praharaj
Sep 19, 2020·Patient Preference and Adherence·Brennan Carrithers, Rif S El-Mallakh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Expert Opinion on Pharmacotherapy
Jeffrey Rado, Philip G Janicak
Biochemistry
Michael J KeiserBrian K Shoichet
© 2021 Meta ULC. All rights reserved